Despite significant advances in the screening, detection, and treatment of preinvasive
cervical lesions, invasive cervical cancer is the fifth most common cancer in European
women. There are large disparities in Europe and worldwide in the incidence, management,
and mortality of cervical cancer.
The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy
and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop
clinically relevant and evidence-based guidelines in order to improve the quality
of care for women with cervical cancer across Europe and worldwide.
The ESGO/ESTRO/ESP nominated an international multidisciplinary development group
consisting of practicing clinicians and researchers who have demonstrated leadership
and expertise in the care and research of cervical cancer (23 experts across Europe).
To ensure that the guidelines are evidence based, the current literature identified
from a systematic search was reviewed and critically appraised. In the absence of
any clear scientific evidence, judgment was based on the professional experience and
consensus of the development group. The guidelines are thus based on the best available
evidence and expert agreement. Prior to publication, the guidelines were reviewed
by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient
The guidelines cover comprehensively staging, management, and follow-up for patients
with cervical cancer. Management includes fertility sparing treatment; stage T1a,
T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy;
early and locally advanced cervical cancer; primary distant metastatic disease; cervical
cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological
evaluation are defined.
Published online: May 01, 2018
☆These guidelines statements were developed by ESGO, ESTRO and ESP and are published in the International Journal of Gynecological Cancer, Radiotherapy & Oncology and Virchows Archiv.
☆☆Initiated through the European Society of Gynaecological Oncology (ESGO), the decision to develop multidisciplinary guidelines has been made jointly by ESGO, the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP). ESGO has provided administrative support. The only external funding source was a grant from the Institut National du Cancer (France). ESGO, ESTRO, and ESP are nonprofit knowledgeable societies. The Institut National du Cancer is a French government agency.
★The development group (including all authors) is collectively responsible for the decision to submit for publication. D.C. (chair), R.P. (cochair), M.R.R. (cochair), and F.P. (methodologist) have written the first draft of the manuscript. All other contributors have actively participated to the development group, given personal input, reviewed the manuscript, and given final approval before submission.
★★The online version of this article doi: https://doi.org//10.1016/j.radonc.2018.03.003 contains supplementary material, which is available to authorized users.
© 2018 European Society for Gynaecological Oncology, European Society for Radiotherapy and Oncology, and the European Society of Pathology. Published by Elsevier B.V. All rights reserved.